Back
Speaker illustration

Professor Peter John Meikle

Baker Heart and Diabetes Institute, Melbourne (Australia)

Presentations

Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention

Event: ESC Congress 2018

Topic: Lipid-Lowering Agents

Session: Cardiovascular risk and its modification

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources